Announcements Trials

Browse Landscape

Status

Completed 1134 Unknown 314 Terminated 286 Recruiting 209 Active not recruiting 132 Withdrawn 59 Not yet recruiting 54 Suspended 6 No longer available 1 Enrolling by invitation 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Conditions

Urogenital Neoplasms 1

Interventions

trametinib 4 nilotinib 4 elotuzumab 4 dabrafenib 4 Amifampridine 4 regorafenib 3 pembrolizumab 3 midostaurin 3 fludarabine phosphate 3 fludarabine 3 Nivolumab 3 Lenalidomide 3 Ipilimumab 3 Everolimus 3 Dexamethasone 3 Cyclophosphamide 3 Crizotinib 3 Bortezomib 3 Axitinib 3 venetoclax 2 veliparib 2 tazemetostat 2 talimogene laherparepvec 2 navitoclax 2 gallium 68 PSMA-11 2 ceritinib 2 carbon-11 acetate 2 aldesleukin 2 Whole-Body Irradiation 2 Trabectedin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × Docetaxel × Clear all

NCT04060628 2026-01-23

Expanded Access to NanoDoce

NanOlogy, LLC

No longer available

Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡